Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content
Fig. 2 | Cost Effectiveness and Resource Allocation

Fig. 2

From: New all oral therapy for chronic hepatitis C virus (HCV): a novel long-term cost comparison

Fig. 2

a Model 2 flow diagram. Shaded areas estimate the source of 649 individuals from a commercial benefits program comprising 100,000 members who would be expected to receive treatment for HCV within 14 years. This group would be responsible for the treatment and medical burden to the payer over the subsequent 14 years. b Standard of Care: cure rates and therapeutic endpoint probabilities. “Standard of Care” = interferon-based treatments used prior to November, 2013. c All Oral Therapy: cure rates and therapeutic endpoint probabilities. “All Oral Therapy” = various combinations of sofosbuvir, ledipasvir and ribavirin. d Natural course of disease progression: therapeutic endpoint probabilities. “Natural Course of Disease Progression” = no treatment

Back to article page